OBJECTIVE: CYP2B6 variation predicts pharmacokinetic characteristics of its substrates. Consideration for underlying genetic structure is critical to protect against spurious associations with the highly polymorphic CYP2B6 gene. DESIGN: The effect of CYP2B6 variation on response to its substrates, nonnucleoside reverse transcriptase inhibitors (NNRTIs), was explored in the Women's Interagency HIV Study. METHODS: Five putative functional polymorphisms were tested for associations with virologic suppression within 1 year after NNRTI initiation in women naive to antiretroviral agents (n = 91). Principal components were generated to control for population substructure. Logistic regression was used to test the joint effect of rs3745274 and rs28399499, which together indicate slow, intermediate, and extensive metabolizers. RESULTS: Rs3745274 was significantly associated with virologic suppression [odds ratio = 3.61, 95% confidence interval (CI) 1.16-11.22, P trend = 0.03]; the remaining polymorphisms tested were not significantly associated with response. Women classified as intermediate and slow metabolizers were 2.90 (95% CI 0.79-12.28) and 13.44 (95% CI 1.66 to infinity) times as likely to achieve virologic suppression compared to extensive metabolizers after adjustment for principal components (P trend = 0.005). Failure to control for genetic ancestry resulted in substantial confounding of the relationship between the metabolizer phenotype and treatment response. CONCLUSION: The CYP2B6 metabolizer phenotype was significantly associated with virologic response to NNRTIs; this relationship would have been masked by simple adjustment for self-reported ethnicity. Given the appreciable genetic heterogeneity that exists within self-reported ethnicity, these results exemplify the importance of characterizing underlying genetic structure in pharmacogenetic studies. Further follow-up of the CYP2B6 metabolizer phenotype is warranted, given the potential clinical importance of this finding.
OBJECTIVE:CYP2B6 variation predicts pharmacokinetic characteristics of its substrates. Consideration for underlying genetic structure is critical to protect against spurious associations with the highly polymorphic CYP2B6 gene. DESIGN: The effect of CYP2B6 variation on response to its substrates, nonnucleoside reverse transcriptase inhibitors (NNRTIs), was explored in the Women's Interagency HIV Study. METHODS: Five putative functional polymorphisms were tested for associations with virologic suppression within 1 year after NNRTI initiation in women naive to antiretroviral agents (n = 91). Principal components were generated to control for population substructure. Logistic regression was used to test the joint effect of rs3745274 and rs28399499, which together indicate slow, intermediate, and extensive metabolizers. RESULTS:Rs3745274 was significantly associated with virologic suppression [odds ratio = 3.61, 95% confidence interval (CI) 1.16-11.22, P trend = 0.03]; the remaining polymorphisms tested were not significantly associated with response. Women classified as intermediate and slow metabolizers were 2.90 (95% CI 0.79-12.28) and 13.44 (95% CI 1.66 to infinity) times as likely to achieve virologic suppression compared to extensive metabolizers after adjustment for principal components (P trend = 0.005). Failure to control for genetic ancestry resulted in substantial confounding of the relationship between the metabolizer phenotype and treatment response. CONCLUSION: The CYP2B6 metabolizer phenotype was significantly associated with virologic response to NNRTIs; this relationship would have been masked by simple adjustment for self-reported ethnicity. Given the appreciable genetic heterogeneity that exists within self-reported ethnicity, these results exemplify the importance of characterizing underlying genetic structure in pharmacogenetic studies. Further follow-up of the CYP2B6 metabolizer phenotype is warranted, given the potential clinical importance of this finding.
Authors: Clive J Hoggart; Eteban J Parra; Mark D Shriver; Carolina Bonilla; Rick A Kittles; David G Clayton; Paul M McKeigue Journal: Am J Hum Genet Date: 2003-06 Impact factor: 11.025
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: David W Haas; Laura M Smeaton; Robert W Shafer; Gregory K Robbins; Gene D Morse; Line Labbe; Grant R Wilkinson; David B Clifford; Richard T D'Aquila; Victor De Gruttola; Richard B Pollard; Thomas C Merigan; Martin S Hirsch; Alfred L George; John P Donahue; Richard B Kim Journal: J Infect Dis Date: 2005-11-01 Impact factor: 5.226
Authors: Sandra G Heil; Marchina E van der Ende; Paul W Schenk; Ilse van der Heiden; Jan Lindemans; David Burger; Ron H N van Schaik Journal: Ther Drug Monit Date: 2012-04 Impact factor: 3.681
Authors: Indrani Halder; Bao-Zhu Yang; Henry R Kranzler; Murray B Stein; Mark D Shriver; Joel Gelernter Journal: Hum Mutat Date: 2009-09 Impact factor: 4.878
Authors: Roman Kosoy; Rami Nassir; Chao Tian; Phoebe A White; Lesley M Butler; Gabriel Silva; Rick Kittles; Marta E Alarcon-Riquelme; Peter K Gregersen; John W Belmont; Francisco M De La Vega; Michael F Seldin Journal: Hum Mutat Date: 2009-01 Impact factor: 4.878
Authors: Ellen M McDonagh; Johnathan L Lau; Maria L Alvarellos; Russ B Altman; Teri E Klein Journal: Pharmacogenet Genomics Date: 2015-07 Impact factor: 2.089
Authors: Vinay K Cheruvu; Robert P Igo; Richard J Jurevic; David Serre; Peter A Zimmerman; Benigno Rodriguez; Rajeev K Mehlotra Journal: J Acquir Immune Defic Syndr Date: 2014-05-01 Impact factor: 3.731
Authors: Melissa A Frasco; Roksana Karim; David Van Den Berg; Richard M Watanabe; Kathryn Anastos; Mardge Cohen; Stephen J Gange; Deborah R Gustafson; Chenglong Liu; Phyllis C Tien; Wendy J Mack; Celeste L Pearce Journal: AIDS Date: 2014-07-31 Impact factor: 4.177
Authors: Sean S Brummel; Kumud K Singh; Adam X Maihofer; Mona Farhad; Min Qin; Terry Fenton; Caroline M Nievergelt; Stephen A Spector Journal: J Acquir Immune Defic Syndr Date: 2016-04-15 Impact factor: 3.731
Authors: Vasantha Jotwani; Michael G Shlipak; Rebecca Scherzer; Rulan S Parekh; W H Linda Kao; Michael Bennett; Mardge H Cohen; Marek Nowicki; Anjali Sharma; Mary Young; Phyllis C Tien; Chirag R Parikh; Michelle M Estrella Journal: Am J Kidney Dis Date: 2015-04-24 Impact factor: 8.860
Authors: Alessandro Cozzi-Lepri; Marc Noguera-Julian; Francesca Di Giallonardo; Rob Schuurman; Martin Däumer; Sue Aitken; Francesca Ceccherini-Silberstein; Antonella D'Arminio Monforte; Anna Maria Geretti; Clare L Booth; Rolf Kaiser; Claudia Michalik; Klaus Jansen; Bernard Masquelier; Pantxika Bellecave; Roger D Kouyos; Erika Castro; Hansjakob Furrer; Anna Schultze; Huldrych F Günthard; Francoise Brun-Vezinet; Roger Paredes; Karin J Metzner Journal: J Antimicrob Chemother Date: 2014-10-21 Impact factor: 5.790
Authors: Sam S Oh; Joshua Galanter; Neeta Thakur; Maria Pino-Yanes; Nicolas E Barcelo; Marquitta J White; Danielle M de Bruin; Ruth M Greenblatt; Kirsten Bibbins-Domingo; Alan H B Wu; Luisa N Borrell; Chris Gunter; Neil R Powe; Esteban G Burchard Journal: PLoS Med Date: 2015-12-15 Impact factor: 11.069